In vitro activity of PR-39, a proline-arginine-rich peptide, against susceptible and multi-drug-resistant Mycobacterium tuberculosis.

We have investigated the in vitro activity of antimicrobial peptides against Mycobacterium tuberculosis using a radiometric method and cfu determinations. PR-39, a proline-arginine-rich antibacterial peptide from porcine leucocytes, was found to be active against drug-susceptible as well as multi-drug-resistant (MDR) clinical isolates of M. tuberculosis. The activity of PR-39 was concentration dependent, with 80% growth inhibition of M. tuberculosis H37Rv at 50 mg/L. The MDR M. tuberculosis strains E1380/94 and P34/95 were less susceptible to PR-39, with 39 and 49% growth inhibition at 50 mg/L peptide, respectively, suggesting a lower susceptibility than strain H37Rv and drug-susceptible clinical isolates. Reduction of counts of M. tuberculosis H37Rv and the MDR M. tuberculosis strain E1380/94 by PR-39 indicated that the growth inhibition seen in the radiometric assay is due to a mycobactericidal effect of the peptide. These observations suggest that antimicrobial peptides may play an important role in host defence against MDR M. tuberculosis.

[1]  T. Ganz,et al.  Monocyte-chemotactic activity of defensins from human neutrophils. , 1989, The Journal of clinical investigation.

[2]  R. Gallo,et al.  PR-39, a Syndecan-inducing Antimicrobial Peptide, Binds and Affects p130Cas * , 1998, The Journal of Biological Chemistry.

[3]  H. Kalbacher,et al.  Inactivation of the dlt Operon inStaphylococcus aureus Confers Sensitivity to Defensins, Protegrins, and Other Antimicrobial Peptides* , 1999, The Journal of Biological Chemistry.

[4]  W. Shafer,et al.  Modulation of Neisseria gonorrhoeae susceptibility to vertebrate antibacterial peptides due to a member of the resistance/nodulation/division efflux pump family. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[5]  D. S. McVey,et al.  Antibacterial activity of a synthetic peptide (PR-26) derived from PR-39, a proline-arginine-rich neutrophil antimicrobial peptide , 1996, Antimicrobial agents and chemotherapy.

[6]  M. Denis.  Human neutrophils, activated with cytokines or not, do not kill virulent Mycobacterium tuberculosis. , 1991, The Journal of infectious diseases.

[7]  P. Spagnuolo,et al.  Evidence for activation of a respiratory burst in the interaction of human neutrophils with Mycobacterium tuberculosis , 1987, Infection and immunity.

[8]  C. Ross,et al.  Chemoattractant properties of PR‐39, a neutrophil antibacterial peptide , 1997, Journal of leukocyte biology.

[9]  G Middlebrook,et al.  Automatable radiometric detection of growth of Mycobacterium tuberculosis in selective media. , 1977, The American review of respiratory disease.

[10]  B. Andersen,et al.  Killing of Mycobacterium tuberculosis by neutrophils: a nonoxidative process. , 1990, The Journal of infectious diseases.

[11]  T. Ganz.  Extracellular release of antimicrobial defensins by human polymorphonuclear leukocytes , 1987, Infection and immunity.

[12]  M. Iseman,et al.  Determination of ansamycin MICs for Mycobacterium avium complex in liquid medium by radiometric and conventional methods , 1985, Antimicrobial Agents and Chemotherapy.

[13]  T. Ganz,et al.  Activity of defensins from human neutrophilic granulocytes against Mycobacterium avium-Mycobacterium intracellulare , 1992, Infection and immunity.

[14]  M. Iseman,et al.  Ethambutol MICs and MBCs for Mycobacterium avium complex and Mycobacterium tuberculosis , 1986, Antimicrobial Agents and Chemotherapy.

[15]  V. Mutt,et al.  Amino acid sequence of PR-39. Isolation from pig intestine of a new member of the family of proline-arginine-rich antibacterial peptides. , 1991, European journal of biochemistry.

[16]  R. B. Merrifield,et al.  Synthesis and antibacterial action of cecropin and proline-arginine-rich peptides from pig intestine. , 2009, The journal of peptide research : official journal of the American Peptide Society.

[17]  Samuel I. Miller,et al.  Lipid A Acylation and Bacterial Resistance against Vertebrate Antimicrobial Peptides , 1998, Cell.

[18]  J. Johansson,et al.  Secondary structure and membrane interaction of PR-39, a Pro+Arg-rich antibacterial peptide. , 1994, European journal of biochemistry.

[19]  R. Appelberg,et al.  Neutrophils Play a Protective Nonphagocytic Role in Systemic Mycobacterium tuberculosis Infection of Mice , 2000, Infection and Immunity.

[20]  C. Ross,et al.  PR-39, a proline-rich antibacterial peptide that inhibits phagocyte NADPH oxidase activity by binding to Src homology 3 domains of p47 phox. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[21]  D. Snider,et al.  Rapid drug-susceptibility testing of Mycobacterium tuberculosis. , 1981, The American review of respiratory disease.

[22]  E. Böttger,et al.  Correlation of molecular resistance mechanisms and phenotypic resistance levels in streptomycin-resistant Mycobacterium tuberculosis , 1996, Antimicrobial agents and chemotherapy.

[23]  A. Rao,et al.  In vitro activity of the antimicrobial peptides human and rabbit defensins and porcine leukocyte protegrin against Mycobacterium tuberculosis , 1996, Infection and immunity.

[24]  J. Ernst,et al.  Roles of calcium and annexins in phagocytosis and elimination of an attenuated strain of Mycobacterium tuberculosis in human neutrophils. , 1998, Microbial pathogenesis.

[25]  C. Ross,et al.  Salmonella infection increases porcine antibacterial peptide concentrations in serum , 1997, Clinical and diagnostic laboratory immunology.

[26]  H. Jörnvall,et al.  Antibacterial components in bronchoalveolar lavage fluid from healthy individuals and sarcoidosis patients. , 1999, American journal of respiratory and critical care medicine.

[27]  V. Mutt,et al.  Spleen antibacterial peptides: high levels of PR-39 and presence of two forms of NK-lysin , 1999, Cellular and Molecular Life Sciences CMLS.

[28]  B. Andersen,et al.  Capacity of human neutrophils to kill Mycobacterium tuberculosis. , 1987, The Journal of infectious diseases.

[29]  G. Khuller,et al.  Biochemical interaction of human neutrophil peptide-1 with Mycobacterium tuberculosis H37Ra , 1999, Archives of Microbiology.

[30]  H. G. Boman,et al.  Mechanisms of action on Escherichia coli of cecropin P1 and PR-39, two antibacterial peptides from pig intestine , 1993, Infection and immunity.

[31]  M. Klagsbrun,et al.  Syndecans, cell surface heparan sulfate proteoglycans, are induced by a proline-rich antimicrobial peptide from wounds. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[32]  D. Andreu,et al.  Animal antimicrobial peptides: an overview. , 1998, Biopolymers.

[33]  S. Hoffner,et al.  In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis. , 1997, The Journal of antimicrobial chemotherapy.

[34]  H. G. Boman,et al.  Peptide antibiotics and their role in innate immunity. , 1995, Annual review of immunology.